These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9247034)

  • 1. [Antigen presentation and macrophages].
    Toubert A; Charron D
    Pathol Biol (Paris); 1997 Feb; 45(2):126-30. PubMed ID: 9247034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA system, antigen processing and presentation.
    Krensky AM
    Kidney Int Suppl; 1997 Mar; 58():S2-7. PubMed ID: 9067934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes.
    Brown MG; Driscoll J; Monaco JJ
    Nature; 1991 Sep; 353(6342):355-7. PubMed ID: 1922341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phagosomes are competent organelles for antigen cross-presentation.
    Houde M; Bertholet S; Gagnon E; Brunet S; Goyette G; Laplante A; Princiotta MF; Thibault P; Sacks D; Desjardins M
    Nature; 2003 Sep; 425(6956):402-6. PubMed ID: 14508490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading.
    Benham AM; Grommé M; Neefjes J
    J Immunol; 1998 Jul; 161(1):83-9. PubMed ID: 9647210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation.
    Benham AM; Neefjes JJ
    J Immunol; 1997 Dec; 159(12):5896-904. PubMed ID: 9550386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
    Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
    J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Human major histocompatibility complex: the HLA system].
    Charron D; Khalil I
    Rev Prat; 1994 Jan; 44(1):20-7. PubMed ID: 8178053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain.
    Hansson GK; Jonasson L; Holm J; Claesson-Welsh L
    Clin Exp Immunol; 1986 May; 64(2):261-8. PubMed ID: 3527502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-proteasomal antigen processing for major histocompatibility complex class I presentation.
    Rock KL; York IA; Goldberg AL
    Nat Immunol; 2004 Jul; 5(7):670-7. PubMed ID: 15224092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPPP: MHC class I antigenic peptide processing prediction.
    Hakenberg J; Nussbaum AK; Schild H; Rammensee HG; Kuttler C; Holzhütter HG; Kloetzel PM; Kaufmann SH; Mollenkopf HJ
    Appl Bioinformatics; 2003; 2(3):155-8. PubMed ID: 15130801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome activator 11 S REG (PA28) and class I antigen presentation.
    Rechsteiner M; Realini C; Ustrell V
    Biochem J; 2000 Jan; 345 Pt 1(Pt 1):1-15. PubMed ID: 10600633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation.
    Barel MT; Pizzato N; van Leeuwen D; Bouteiller PL; Wiertz EJ; Lenfant F
    Eur J Immunol; 2003 Jun; 33(6):1707-16. PubMed ID: 12778489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of proteasomes and antigen processing.
    Monaco JJ; Nandi D
    Annu Rev Genet; 1995; 29():729-54. PubMed ID: 8825492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.